Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy ...

Small-cell lung cancer (SCLC ... If you have regional stage SCLC, it means your cancer has spread outside your lung to nearby areas. The 5-year survival rate for this type is 18%.

The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

IMFINZITM (durvalumab) has received approval in the European Union as a monotherapy for treating adults with limited-stage ...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for ...

Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.

Lung Cancer Test Predicts Survival in Early Stages Better Than Current Methods ... that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations ...

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

Lung cancer is the one of the most common types of cancer doctors diagnose each year in the U.S. The most common kind of lung cancer is non-small-cell lung ... dropped 1.4% each year in women.